Drugs / ALXN2220
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04360434 | Feb 2020 → Jul 2023 | — | Neurimmune AG | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07608354 | Jun 2026 → Feb 2029 expected | amyloidosis | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07213583 | Aug 2025 → Oct 2026 expected | — | Neurimmune AG | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06183931 | Jan 2024 → Jun 2027 expected | amyloidosis | Alexion Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2026-06-26 | Neurimmune AG | Results Cliramitug Phase 1 Long-Term Follow-Up Data Published in Nature Medicine neurimmune.com ↗
The new data demonstrated dose- and time-dependent effects on amyloid depletion, cardiac biomarkers and cardiac structure and function in participants who continued treatment in the NI006-101 open-label extensions. |
| 2025-08-26 | Neurimmune AG | Results Echocardiographic treatment response and long-term tolerability of cardiac ATTR depleter cliramitug to be presented at ESC Congress 2025 neurimmune.com ↗ |
| 2024-10-14 | Neurimmune AG | Regulatory FDA Fast Track Designation for ALXN2220 for Depletion of Cardiac ATTR neurimmune.com ↗
Neurimmune today announced that the U.S. Food and Drug Administration (FDA) has granted Alexion, AstraZeneca Rare Disease Fast Track designation for the development of ALXN2220 (formerly NI006) for the treatment of transthyretin amyloidosis with cardiomyopathy (ATTR-CM). |
| 2024-05-23 | Neurimmune AG | Results Multiple Poster Presentations on ALXN2220 for Cardiac ATTR Amyloid Depletion to be Presented at the XIX International Symposium on Amyloidosis neurimmune.com ↗
Initial treatment with ALXN2220 was well tolerated with a transient increase in C-reactive proteins, suggesting initial targeted immune activation and recruitment of phagocytic immune cells. |
| 2023-05-20 | Neurimmune AG | Results Promising Phase 1 results for antibody NI006 in ATTR cardiomyopathy published in The New England Journal of Medicine neurimmune.com ↗
Results indicate that the safety profile of NI006 is favorable up to the highest dose tested. |
All press releases naming this drug 14 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALXN2220 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06183931 ↗ |
| Known as | NI006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04360434 ↗ |
| Route | Intravenous | “NI006 will be administered intravenously” NCT04360434 ↗ |